Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)

SUPPLEMENTARY MATERIALS
General information
All reagents and solvents were purchased from commercial sources and used as obtained.
1 H NMR and 13 C NMR spectra were recorded with a Bruker 400 NMR spectrometer and referenced to deuterium dimethyl sulfoxide ). Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak. LC/MS were performed on an Agilent 6224 TOF using an ESI source coupled to an Agilent 1260 Infinity HPLC system operating in reverse mode with an Agilent XDB-C18 column (4.6 × 50 mm, 1.8 μm) using a water/ acetonitrile (each with 0.2% (v/v) formic acid) gradient at a flow rate at 0.4 mL/min. Flash column chromatography was conducted using silica gel (Silicycle 40−64 μm). The purities of all compounds were determined to be above 95% by HPLC.
Chemical synthesis and characterization of CHMFL-KIT-031
Methyl (3,4,5-trimethoxybenzoyl)glycinate (1) To a solution of 3,4,5-trimethoxybenzoic acid (1.1 g, 5.2 mmol) in DMF (20 mL) were added glycine methyl ester hydrochloride (0.8 g, 6.4 mmol), HATU (3.0 g, 7.8 mmol), and DIEA (1.3 g, 10.4 mmol). The resulting mixture was stirred at room temperature for 30 min. Then it was diluted with EtOAc (150 mL), washed with water (100 mL× 3) and brine (100 mL). The organic layers were dried over anhydrous sodium sulfate, concentrated and purified by silica gel flash chromatography (0−2% MeOH in DCM) to afford compound 1 (1.2 g, 82%) as a white solid. (3,4,5-Trimethoxybenzoyl)glycine (2) To a solution of 1 (1.0 g, 3.5 mmol) in THF (15 mL) were added LiOH (0.8 g, 35.3 mmol) and water (15 mL). The reaction mixture was stirred at room temperature for 2 h under argon protection. The mixture was acidified with hydrochloric acid and the solution was extracted with ethyl acetate (100 mL). The organic solution was washed with diluted hydrochloric acid (50 mL) and brine (50 mL). The organic layers were dried over anhydrous sodium sulfate, and evaporated to give the title compound 2 (0.8 g, 85%) as a white solid. (E)-3,4,5-Trimethoxy-N-(2-oxo-2-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl) amino)ethyl)benzamide (3) To a solution of 2 (0.6 g, 2.2 mmol) in DMF (15 mL) were added (E)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine (0.9 g, 2.7 mmol), HATU (1.3 g, 3.3 mmol) and DIEA (0.6 g, 4.4 mmol). The resulting mixture was stirred at room temperature for 30 min. Then it was diluted with ethyl acetate (120 mL), washed with water (80 mL× 3) and brine (80 mL). The organic layers were dried over anhydrous sodium sulfate, concentrated and purified by silica gel flash chromatography (0−5% MeOH in DCM) to afford compound 3 (1.1 g, 88%) 77, 166.60, 155.26, 153.07, 150.04, 141.75, 141.51, 140.58, 138.41, 137.34, 130.32, 129.59, 123.84, 123.14, 123.04, 121.72, 118.87, 115.94, 105.43, 100.10, 84.96, 67.10, 60.57, 56.47, 43.96, 29.27, 25.29, 22.50 
CHMFL-KIT-031.
Compound 3 (1.0 g, 1.8 mmol) was dissolved in dichloromethane (8 mL) and TFA (8 mL) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was then concentrated in vacuo and acidified with saturated aqueous sodium bicarbonate and the solids were filtered, washed with water (200 mL) and dried at 40° C for 48 h to provide CHMFL-KIT-031 (0.8 g, 91%) as a yellow solid. 75, 166.60, 155.00, 153.07, 149.13, 142.48, 142.02, 140.57, 138.21, 138.02, 129.59, 128.21, 125.51, 123.09, 123.03, 121.38, 117.55, 115.34, 105.43, 99.79, 60.56, 56.46, 43.99 
